首页> 美国卫生研究院文献>Synthetic and Systems Biotechnology >Streamlining the preparation of endotoxin-free ClearColi cell extract with autoinduction media for cell-free protein synthesis of the therapeutic protein crisantaspase
【2h】

Streamlining the preparation of endotoxin-free ClearColi cell extract with autoinduction media for cell-free protein synthesis of the therapeutic protein crisantaspase

机译:使用自动诱导培养基简化无内毒素 ClearColi细胞提取物的制备过程以无细胞蛋白质合成治疗性蛋白质crisantaspase

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

An “endotoxin-free” -based cell-free protein synthesis system has been reported to produce therapeutic proteins rapidly and on-demand. However, preparation of the most complex CFPS reagent – the cell extract – remains time-consuming and labor-intensive because of the relatively slow growth kinetics of the endotoxin-free ClearColi BL21(DE3) strain. Here we report a streamlined procedure for preparing cell extract from ClearColi™ using auto-induction media. In this work, the term auto-induction describes cell culture media which eliminates the need for manual induction of protein expression. Culturing Clearcoli™ cells in autoinduction media significantly reduces the hands-on time required during extract preparation, and the resulting “endotoxin-free” cell extract maintained the same cell-free protein synthesis capability as extract produced with traditional induction as demonstrated by the high-yield expression of crisantaspase, an FDA approved leukemia therapeutic. It is anticipated that this work will lower the barrier for researchers to enter the field and use this technology as the method to produce endotoxin-free -based extract for CFPS.
机译:据报道,基于“无内毒素”的无细胞蛋白质合成系统可快速,按需生产治疗性蛋白质。但是,由于无内毒素的ClearColi BL21(DE3)菌株的生长动力学相对较慢,因此制备最复杂的CFPS试剂(细胞提取物)仍然很费时且费力。在这里,我们报告了使用自动诱导培养基从ClearColi™制备细胞提取物的简化程序。在这项工作中,术语“自动诱导”描述了不需要手动诱导蛋白质表达的细胞培养基。在自动诱导培养基中培养Clearcoli™细胞可大大减少提取物制备过程中所需的动手时间,所得的“无内毒素”细胞提取物与传统诱导产生的提取物保持了相同的无细胞蛋白质合成能力,高可产生crisantaspase(一种FDA批准的白血病治疗药物)的表达。预计这项工作将降低研究人员进入该领域的障碍,并将这项技术用作生产无内毒素的CFPS提取物的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号